文献速递淋巴瘤白血病

B细胞受体与NOTCH1在慢性淋巴细胞白血病及Richter综合征中的双向联系:治疗意义

Bidirectional linkage between the B-cell receptor and NOTCH1 in chronic lymphocytic leukemia and in Richter's syndrome: therapeutic implications.
PubMed 文献 · Leukemia · 2019-08-29

研究在原发性CLL细胞中证实NOTCH1与BCR通路存在双向功能联系:NOTCH1激活上调表面IgM及LYN、BTK、BLNK表达,增强BCR信号;BCR交联则促进NOTCH1翻译与表面表达,并诱导钙动员辅助配体非依赖性NOTCH1激活。γ-分泌酶抑制剂DAPT联合依鲁替尼在体外及短期人源异种移植模型中显著增强依鲁替尼效果,在Richter综合征PDX中联合治疗降低疾病负荷并提高总生存。

要点

  • NOTCH1与BCR通路双向互作,支持双靶向抑制策略。
  • DAPT联合依鲁替尼在体外及PDX中增强依鲁替尼疗效。
  • 联合方案在Richter综合征PDX中降低疾病负荷、提高总生存。

核心结论

  • NOTCH1与BCR通路存在双向功能联系,为双抑制策略提供依据。
  • DAPT联合依鲁替尼在体外和短期PDX中显著增强依鲁替尼效果。
  • 联合治疗在Richter综合征PDX中降低疾病负荷并提高总生存。

研究设计与样本

  • 研究使用高度均一的原发性CLL细胞样本。
  • 体外实验结合短期患者来源异种移植模型。
  • 另用Richter综合征患者来源异种移植(RS-PDX)模型验证联合治疗。

主要发现

  • NOTCH1激活增加表面IgM及LYN、BTK、BLNK表达,增强BCR信号反应包括整体mRNA翻译。
  • BCR交联促进NOTCH1自身翻译及细胞表面表达增加。
  • BCR连接诱导钙动员,可促进配体非依赖性NOTCH1激活。
  • DAPT联合依鲁替尼在体外和短期PDX中显著增强依鲁替尼效果。
  • 依鲁替尼联合DAPT治疗RS-PDX降低疾病负荷并提高总生存。

临床怎么用

  • 对NOTCH1突变CLL可考虑NOTCH1与BCR通路双抑制策略。
  • Richter综合征治疗选择有限,联合依鲁替尼与γ-分泌酶抑制剂值得探索。

局限性

  • 短期PDX模型结果需进一步临床验证。
  • 双抑制策略在CLL领域的应用可能有限,更多相关于Richter综合征管理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

NOTCH1 mutations in chronic lymphocytic leukemia (CLL) lead to accumulation of NOTCH1 intracellular domain (NICD) and prolong signaling. These mutations associate with a more aggressive disease compared to wild-type (WT) CLL. In this work we demonstrate a bidirectional functional relationship between NOTCH1 and the B cell receptor (BCR) pathways. By using highly homogeneous cohorts of primary CLL cells, activation of NOTCH1 is shown to increase expression of surface IgM, as well as LYN, BTK, and BLNK, ultimately enhancing BCR signaling responses, including global mRNA translation. Upon BCR cross-linking, NOTCH1 itself is actively translated and increased on cell surface. Furthermore, BCR ligation induces calcium mobilization that can facilitate ligand-independent NOTCH1 activation. These data suggest that the two pathways are functionally linked, providing a rationale for dual inhibition strategies. Consistently, addition of the γ-secretase inhibitor DAPT to ibrutinib significantly potentiates its effects, both in vitro and in a short-term patient-derived xenograft model. While this observation may find limited applications in the CLL field, it is more relevant for Richter's Syndrome (RS) management, where very few successful therapeutic options exist. Treatment of RS-patient-derived xenografts (RS-PDX) with the combination of ibrutinib and DAPT decreases disease burden and increases overall survival.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Arruga F, Bracciamà V, Vitale N, et al. Bidirectional linkage between the B-cell receptor and NOTCH1 in chronic lymphocytic leukemia and in Richter's syndrome: therapeutic implications. Leukemia. 2019. PMID: 31467429. doi:10.1038/s41375-019-0571-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。